新型衣壳抑制剂来那卡帕韦治疗高度经治HIV感染者的耐药性分析
CAPELLA研究纳入对4类主要抗逆转录病毒药物中至少3类耐药且每类至少2种药物耐药的高病毒载量高度经治HIV感染者,评估来那卡帕韦联合优化背景方案的耐药性。治疗26周时81%参与者实现病毒抑制,8例在无意功能性单药治疗期间出现来那卡帕韦耐药突变。
要点
- 基线时46%参与者对4类主要抗逆转录病毒药物均耐药。
- 来那卡帕韦联合优化背景方案治疗26周,81%参与者实现病毒抑制。
- 8例在无意功能性单药治疗期间出现来那卡帕韦耐药突变。
核心结论
- 来那卡帕韦联合优化背景方案在高度经治多重耐药HIV感染者中高效,但无意作为功能性单药使用时可能选择耐药。
研究设计与样本
- CAPELLA为关键的2/3期研究,纳入对4类主要抗逆转录病毒药物中至少3类耐药且每类至少2种药物耐药的高病毒载量高度经治HIV感染者。
- 基线耐药分析采用商业检测(HIV-1蛋白酶、逆转录酶、整合酶基因型/表型检测)。
- 基线后耐药在经历病毒学失败的参与者中评估。
主要发现
- 基线时46%参与者对4类主要抗逆转录病毒药物耐药,三分之一参与者已耗尽4类主要抗逆转录病毒药物中至少3类的所有药物。
- 来那卡帕韦联合优化背景方案治疗26周,81%参与者实现病毒抑制。
- 基线后出现来那卡帕韦耐药突变的8例参与者中,6例为M66I,1例为K70H,1例为Q67H+K70R;这些参与者在耐药选择时正接受无意功能性来那卡帕韦单药治疗。
临床怎么用
- 作者指出,来那卡帕韦联合优化背景方案在高度经治多重耐药HIV感染者中高效,但无意作为功能性单药使用时可能选择耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenacapavir (LEN) is a first-in-class inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function in clinical development for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) harboring multidrug resistance (MDR) in combination with an optimized background regimen (OBR). Here we describe resistance analyses conducted in the pivotal phase 2/3 CAPELLA study. METHODS: CAPELLA enrolled viremic HTE PWH with resistance to ≥3 of 4 of the main antiretroviral (ARV) classes and resistance to ≥2 ARV drugs per class. Baseline resistance analyses used commercial assays (HIV-1 protease, reverse transcriptase, integrase genotypic/phenotypic tests). Postbaseline resistance was evaluated in participants experiencing virologic failure. RESULTS: At baseline, 46% of participants had resistance to the 4 main ARV drug classes, with one-third of participants having exhausted all drugs from ≥3 of the 4 main ARV classes. Treatment with LEN + OBR for 26 weeks led to viral suppression in 81% of participants. Postbaseline resistance mutations to lenacapavir occurred in 8 participants (6 with M66I, 1 with K70H, 1 with Q67H + K70R) who were receiving unintended functional LEN monotherapy at the time of resistance selection. CONCLUSIONS: LEN added to OBR led to high efficacy in this HTE patient population with MDR but could select for resistance when used unintentionally as functional monotherapy.
引用
- Margot NA, Naik V, VanderVeen L, et al. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir. J Infect Dis. 2022. PMID: 36082606. doi:10.1093/infdis/jiac364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。